Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | MMP1 | P03956 | 1/20 | 0.31 |
| ▸ | MMP2 | P08253 | 1/20 | 0.31 |
| ▸ | MMP9 | P14780 | 1/20 | 0.31 |
| ▸ | MMP8 | P22894 | 1/20 | 0.31 |
| ▸ | MMP13 | P45452 | 1/20 | 0.31 |
| ▸ | ACHE | P22303 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8720547 | 0.73 | TSHR (0.32) | TSHRSMN1; SMN2 | |
| SCHEMBL64466 | 0.73 | ACP1 (0.35) | CA1CA2MMP1MMP2MMP9 | |
| SCHEMBL14964903 | 0.65 | TSHR (0.39) | TSHRSMN1; SMN2 | |
| SCHEMBL65865 | 0.64 | CES2 (0.36) | CA1CA2MMP1ACHE | |
| SCHEMBL795355 | 0.63 | MEN1 (0.41) | CA1CA2MMP1MMP2MMP9 | |
| Pyrogallol SCHEMBL16714223 | 0.59 | ALDH1A1 (0.57) | PTPN1CA1CA2MMP2MMP9 | |
| Pyrogallol SCHEMBL704091 | 0.59 | ALDH1A1 (0.57) | PTPN1CA1CA2MMP2MMP9 | |
| SCHEMBL30035768 | 0.58 | CA1 (0.66) | CA1CA2MMP1MMP2MMP9 | |
| SCHEMBL1894783 | 0.58 | CA1 (0.66) | CA1CA2MMP1MMP2MMP9 | |
| SCHEMBL14964902 | 0.58 | TSHR (0.32) | ACHETSHRSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1857452-A1 | CONDENSATION COMPOUND BETWEEN FLUORINATED CYCLOPENTANE RING AND AROMATIC RING, AND PROCESS FOR PRODUCING THE SAME | OSAKA UNIVERSITY (JP) | 2007-11-21 | — | — | EP | claimed |
| US-20230272272-A1 | Surface Treatment Of Quantum Dots | UNITED STATES DEPARTMENT OF ENERGY | 2023-08-31 | — | — | US | disclosed |
| US-8207184-B2 | Condensation compound between fluorinated cyclopentane ring and aromatic ring, and process for producing the same | SUMITOMO CHEMICAL CO., LTD. (JP) | 2012-06-26 | — | — | US | disclosed |
| US-8129400-B2 | Condensation compound between fluorinated cyclopentane ring and aromatic ring, and process for producing the same | SUMITOMO CHEMICAL CO., LTD. (JP) | 2012-03-06 | — | — | US | disclosed |
| US-8114956-B2 | Polymer having unit obtained by condensation of difluorocyclopentanedione ring and aromatic ring, organic thin film using the same, and organic thin film device | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2012-02-14 | — | — | US | disclosed |
| US-20110282073-A1 | CONDENSATION COMPOUND BETWEEN FLUORINATED CYCLOPENTANE RING AND AROMATIC RING, AND PROCESS FOR PRODUCING THE SAME | SUMITOMO CHEMICAL CO., LTD. (JP) | 2011-11-17 | — | — | US | disclosed |
| US-20110213162-A1 | CONDENSATION COMPOUND BETWEEN FLUORINATED CYCLOPENTANE RING AND AROMATIC RING, AND PROCESS FOR PRODUCING THE SAME | SUMITOMO CHEMICAL CO., LTD. (JP) | 2011-09-01 | — | — | US | disclosed |
| US-8008336-B2 | Forming electronic material, semiconductors | SUMITOMO CHEMICAL CO., LTD. (JP) | 2011-08-30 | — | — | US | disclosed |
| US-7932347-B2 | Polymer comprising unit comprising fluorocyclopentane ring fused with aromatic ring and organic thin film and organic thin film element both comprising the same | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2011-04-26 | — | — | US | disclosed |
| US-20100084640-A1 | POLYMER HAVING UNIT OBTAINED BY CONDENSATION OF DIFLUOROCYCLOPENTANEDIONE RING AND AROMATIC RING, ORGANIC THIN FILM USING THE SAME, AND ORGANIC THIN FILM DEVICE | SUMITOMO CHEMICAL COMPANY LIMITED (JP) | 2010-04-08 | — | — | US | disclosed |
| US-6689766-B2 | ALSO FOR TREATING MALIGNANT TUMORS, RHEUMATOID ARTHRITIS, OSTEOPOROSIS, DIABETES MELLITUS, HYPERTENSION, ALOPECIA, ACNE, PSORIASIS, DERMATITIS, HYPERCALCEMIA, HYPOPARATHYROIDISM AND METABOLIC DISORDER OF CARTILAGE. | TEIJIN LIMITED (JP) | 2004-02-10 | — | — | US | disclosed |
| US-6548489-B2 | Also for treating malignant tumors, rheumatoid arthritis, osteoporosis, diabetes mellitus, hypertension, alopecia, acne, psoriasis, dermatitis, hypercalcemia, hypoparathyroidism and metabolic disorder of cartilage. | TEIJIN LIMITED (JP) | 2003-04-15 | — | — | US | disclosed |
| US-6531460-B1 | Vitamin D3 derivatives | TEIJIN LIMITED (JP) | 2003-03-11 | — | — | US | disclosed |
| US-20020132799-A1 | Vitamin D3 dervative and treating agent for inflammatory respiratory disease using same | TEIJIN LIMITED | 2002-09-19 | — | — | US | disclosed |
| US-20020103173-A1 | Vitamin D3 derivative and treating agent for inflammatory respiratory disease using same | TEIJIN LIMITED | 2002-08-01 | — | — | US | disclosed |
| US-20020099039-A1 | Vitamin D3 derivative and treating agent for inflammatory respiratory disease using same | TEIJIN LIMITED | 2002-07-25 | — | — | US | disclosed |
| US-20020091109-A1 | Vitamin D3 derivative and treating agent for inflammatory respiratory disease using same | TEIJIN LIMITED | 2002-07-11 | — | — | US | disclosed |
| EP-1123921-A1 | VITAMIN D 3? DERIVATIVES AND REMEDIES FOR INFLAMMATORY RESPIRATORY DISEASES CONTAINING THE SAME | TEIJIN LIMITED (JP) | 2001-08-16 | — | — | EP | disclosed |
| US-6174628-B1 | ELECTROLYTE HAS HIGH POLARITY, HIGH RESISTANCE TO OXIDATION AND FLAME RETARDANCE, AND THUS POSSESSES EXCELLENT CHARACTERISTICS AS THE ELECTROLYTE FOR ELECTRIC ENERGY GENERATORS | DAIKIN INDUSTRIES, LTD. (JP) | 2001-01-16 | — | — | US | disclosed |
| EP-0948073-A1 | ELECTROLYTIC SOLUTION AND DEVICE FOR GENERATING ELECTRIC ENERGY THEREWITH | Daikin Industries, Ltd. (JP) | 1999-10-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020103173-A1 | Vitamin D3 derivative and treating agent for inflammatory respiratory disease using same | CYP24A1, VDR, CYP2R1 | PTPN1 3342/4885CA1 757/4885CA2 187/4885 |
| US-20020132799-A1 | Vitamin D3 dervative and treating agent for inflammatory respiratory disease using same | CYP24A1, VDR, CYP2R1 | PTPN1 2933/4885CA1 403/4885CA2 117/4885 |
| US-20110213162-A1 | CONDENSATION COMPOUND BETWEEN FLUORINATED CYCLOPENTANE RING AND AROMATIC RING, AND PROCESS FOR PRODUCING THE SAME | RCC1, AFF4, TPR | PTPN1 3622/4885CA1 1537/4885CA2 2187/4885 |
| US-20110282073-A1 | CONDENSATION COMPOUND BETWEEN FLUORINATED CYCLOPENTANE RING AND AROMATIC RING, AND PROCESS FOR PRODUCING THE SAME | RCC1, AFF4, TPR | PTPN1 3622/4885CA1 1537/4885CA2 2187/4885 |
| US-20020099039-A1 | Vitamin D3 derivative and treating agent for inflammatory respiratory disease using same | CYP24A1, VDR, CYP2R1 | PTPN1 3342/4885CA1 757/4885CA2 187/4885 |
| US-20020091109-A1 | Vitamin D3 derivative and treating agent for inflammatory respiratory disease using same | CYP24A1, VDR, CYP2R1 | PTPN1 3342/4885CA1 757/4885CA2 187/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.